Pharmacological profile of reboxetine, a representative of new class of antidepressant drugs, selective noradrenaline reuptake inhibitor (NARI), given acutely

Polish Journal of Pharmacology

Volumn 51, Issue 5, 1999, Pages 399-404

  Rogóz, Zofia ^a   Wróbel, Andrzej ^b   Krasicka Domka, Monika ^b   Maj, Jerzy ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Behavioral antidepressant test; Mice; Rats; Reboxetine

Indexed keywords

ANTIDEPRESSANT AGENT; APOMORPHINE; CLONIDINE; NEUROTRANSMITTER RECEPTOR; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; RESERPINE;

AGGRESSIVENESS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HYPOTHERMIA; IMMOBILIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC UPTAKE INHIBITORS; AGGRESSION; ANIMALS; ANTIDEPRESSIVE AGENTS; APOMORPHINE; CLONIDINE; DOPAMINE AGONISTS; DRUG EVALUATION, PRECLINICAL; HYPOTHERMIA; IMMOBILIZATION; MALE; MICE; MORPHOLINES; MOTOR ACTIVITY; MUSCARINIC AGONISTS; OXOTREMORINE; RATS; RATS, WISTAR; RESERPINE; TREMOR;

EID: 0345634225     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ban T. A., Gaszner P., Aguglia E., Batista R., Castillo A., Lipcsey A., Macher J.-P., Torres-Ruiz A., Vergara L.: Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Hum. Psychopharmacol., 1998, 13, S29-S39.
2. Berzewski H., Van Moffaert M., Gagiano C. A.: Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur. Neuropsychopharmacol., 1997, 7, Suppl. 1, S37-S47.
3. Brunello N., Racagni G.: Rationale for the development of noradrenaline reuptake inhibitors. Hum. Psychopharmacol., 1998, 13, S13-S19.
4. R Symposium, 1998, Cagliari.
5. Healy D., McMonagle T.: The enhancement of social functioning as a therapeutic principle in the management of depression. J. Psychopharmacol., 1997, 11, Suppl. 4, S25-S31.
6. Hindmarch I.: Effect of antidepressants on cognitive and psychomotor function: the lack of effect of reboxetine. Hum. Psychopharmacol., 1998, 13, S21-S27.
7. Maj J., Mogilnicka E., Klimek V., Kordecka-Magiera A.: Chronic treatment with antidepressants: potentiation of clonidine-induced aggression in mice via noradrenergic mechanism. J. Neural Transm., 1981, 52, 189-197.
8. Maj J., Pawlowski L., Wiszniowska G.: The effect of tricyclic antidepressants in apomorphine-induced hypothermia in the mouse. Pol. J. Pharmacol. Pharm., 1974, 26, 329-336.
9. Maj J., Rogóż Z., Skuza G.: 5-Hydroxytryptamine uptake inhibitors antagonize the antireserpine effects of noradrenaline uptake inhibitors. J. Pharm. Pharmacol., 1983, 35, 128-129.
10. Maj J., Rogóż Z., Skuza G., Sowińska H.: The effect of selective inhibitors of noradrenaline and serotonin uptake on reserpine-and apomorphine-induced hypothermia in mice. Pol. J. Pharmacol. Pharm., 1983, 35, 49-57.
11. 2-adrenergic and cholinergic system in mice. Pol. J. Pharmacol. Pharm., 1989, 41, 313-319.
12. Melloni P., Carniel G., Della Torre A., Bonsigniori A., Buonamici A., Pozzi O., Ricciardi S., Rossi A.: Potential antidepressant agents. Alpha-aryloxy-benzyl derivatives of ethanolamine and morpholine. Eur. J. Med. Chem., 1984, 19, 235-242.
13. Montgomery S. A.: Reboxetine additional benefis to the depressed patient. J. Psychopharmacol., 1997, 11, Suppl., S9-S15.
14. Mucci M.: Reboxetine: a review of antidepressant tolerability. J. Psychopharmacol., 1997, 11, Suppl. 4, S33-S37.
15. Ozawa H., Miyauchi T., Sugawara K.: Potentiating effect of lithium chloride on aggressive behaviour induced in mice by nialamide plus L-DOPA and clonidine. Eur. J. Pharmacol., 1975, 34, 169-179.
16. Porsolt R. D., Anton G., Blavet N., Jalfre M.: Behavioral despair in rats, a new model sensitive to antidepressant treatments. Eur. J. Pharmacol., 1978, 47, 379-391.
17. Porsolt R. D., Bertin A., Jalfre M.: Behavioral despair in mice; a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Thér., 1977, 229, 327-336.
18. Puech A. J., Frances H., Simon P.: Imipramine antagonism of apomorphine-induced hypothermia; a non-dopaminergic interaction. Eur. J. Pharmacol., 1978, 47, 125-127.
19. Riva M., Brunello N., Rovescalli A. C., Galimberdi R., Carfagna N., Carminati P., Pozzi O., Ricciardi S., Roncucci R., Rossi A., Racagni G.: Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J. Drug Dev., 1989, 1, 243-253.
20. Rogóż Z., Dziedzicka-Wasylewska M., Maj J.: Pharmacological profile of venlafaxine, a new antidepressant, given acutely. Pol. J. Pharmacol., 1998, 50, 107-115.
21. Rogóż Z., Skuza G., Maj J.: Pharmacological profile of milnacipran, a new antidepressant, given acutelly. Pol. J. Pharmacol., 1999, 51, 317-322.
22. Szabadi E., Bradshow C. M., Boston P. F., Langley R. W.: The human pharmacology of reboxetine. Hum. Psychopharmacol., 1998, 13, S3-S12.
23. Wong E. H. F., Graveel C. R., Smith M. W.: Pharmacological selectivity of reboxetine, a selective noradrenaline reuptake inhibitor (NARI). Presented at the Annual Meeting of the American College of Neuropsychopharmacology, 1997, December, Hawaii.